In this Issue:

Meetings I

In the Know I

Research 2-5

Happenings

August 17, 2014

DEPARTMENT OF PSYCHIATRY

WEEK OF JULY 14-18, 2014

NEWSLETTER

MEETINGS

Thursday 07/17/14 RESIDENT LECTURES

PGY-1, PGY-2, PGY-3, PGY-4 and Child and Adolescent Psychiatry Residents: Please see weekly didactic notice email from the Education Office for scheduled topics and presenters.

Friday 07/18/14 THIRD YEAR MEDICAL STUDENT LECTURES

8:00 AM Child Case Discussion - Dr. Saundra Stock
10:00 AM TBI/Dementia Case Discussion - Dr. Sean Phillips

IN THE KNOW

The Department of Psychiatry and Behavioral Neuroscience takes great pride in announcing the academic advancement of the following members of our department:

Dr. Saundra Stock – Professor
Dr. Jamie Fernandez – Associate Professor
Dr. Brian Giunta – Associate Professor
Dr. Barbara Lubrano – Associate Professor
Dr. Mariann Suarez – Associate Professor

Promotions signify academia’s recognition of sustained contributions to the missions of the College Of Medicine, the public and the field of psychiatry and behavioral neuroscience. Please join me in congratulating each and everyone of our distinguished faculty members on their well earned success. This is a celebratory moment for the department and we wish them continued success in their future academic endeavors. Well Done! - Dr. Kailie Shaw

Continued on page 2
Still Enrolling – Bipolar
A 9-month outpatient study of Ramelteon sub-lingual as an adjunctive treatment to prevent relapse of manic/mixed/depressive symptoms in patients 18-75 years who have experienced a manic/mixed/depressed episode within the last 9 months. Patients will continue on current mood stabilizers, antidepressants, or antipsychotic medications throughout the trial.

Principal Investigator: Carlos Santana, MD

Still Enrolling – Bipolar I Disorder with Depressive Symptoms
An 8-week outpatient study assessing Ramelteon sub-lingual as an adjunctive treatment for patients 18-75 years who are currently experiencing depressive symptoms associated with Bipolar I Disorder.

Principal Investigator: Carlos Santana, MD

Now Enrolling – bvFTD
A 12-Month Safety and Efficacy Trial of study drug in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD). Patients must be under 80 years of age and in general good health. A person with whom patient has regular contact must accompany them to study visits. MRIs, study visits including physical and neuro exams and safety and efficacy testing are provided at no cost. Subjects on stable dose of AChEI, memantine, or both may be enrolled. Subjects are randomly assigned either study drug or placebo at a 1:1 ratio. Please call Kathy at (813)974-7006 to make a referral.

Principal Investigator: Jean Fils, MD

Enrolling soon – Mild Alzheimer’s disease
This is a double-blind, placebo-controlled study to test the safety and effectiveness of an anti-amyloid antibody administered subcutaneously as a disease-modifying treatment in patients age 50 - 90 with mild AD. Stable dose of approved medications for AD will be permitted at study entry. Patients will undergo brain MRI exams for monitoring safety and response to study treatment. They will also undergo safety and cognitive testing. Patients must have a person with whom they are regular contact, who can accompany them to study visits. Please call Kathy at (813)974-7006 to make a referral.

Principal Investigator: Jean Fils, MD

Child and Adolescent with Autistic Disorder Clinical Trial
A 6-week outpatient study of Lurasidone to evaluate efficacy and safety in patients 6-17 years old that are diagnosed with Autistic disorder with irritability. Trial is a double-blind study with a 1:1:1 ratio. Subjects that complete the study will be eligible to participate in a separate 104-week open-label extension study. Please call Colleen at (813) 974-9104 for more information.

Principal Investigator: Daniel Fallon, MD.

Continued on page 3
Antibiotic Treatment Trial for the PANDAS/PANS Phenotype

The purpose of this research study is to know if the antibiotic azithromycin improves symptom severity in children with sudden and severe onset obsessive compulsive symptoms known as PANS, Pediatric Acute Onset Neuropsychiatric Syndrome, and PANDAS, Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus. This study seeks to compare the effects of placebo vs. azithromycin on symptom severity as well as to assess immune risk factors in children with PANDAS/PANS. Your child is being asked to take part in this research study because he/she may meet criteria for PANS/PANDAS and has a current episode of Obsessive-Compulsive Disorder (OCD) symptoms of less than or equal to 6 months that has been associated with an infection. Children ages 4-14 years old who are not currently taking prophylactic antibiotics or undergoing cognitive behavioral therapy (CBT) are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Investigational Medication (AZD5213) for Adolescents with Tourette’s Disorder

The purpose of this research study is to assess the safety, tolerability, and effectiveness of an investigational medication (AZD5213) in adolescents with Tourette’s disorder (TD). AZD5213 is a novel histamine H3 receptor inverse agonist that shows promise for the potential treatment of a variety of indications, including TD. This is a multicenter, randomized, two-part study of AZD5213 in adolescents (ages 12-17 years) with TD. In Part 1 of the study, following an up to 21-day screening period, eligible subjects will receive a single small dose of AZD5213 in-clinic. In Part 2 of the study, each treatment (AZD5213 or placebo) will be administered in two 3-week periods (six treatment periods, total). Each treatment will be received in one of Periods 1-3, and again in one of Periods 4-6. Visits will occur weekly during Part 2 of the study. Some visits will be in-clinic; while other visits will be performed by telephone. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Investigational Medication (Bitopertin) for Adults with OCD

The purpose of this research study is to evaluate an investigational medication (bitopertin) for adults with OCD, and determine if patients treated with bitopertin and a selective serotonin reuptake inhibitor (SSRI) may experience fewer symptoms compared with those treated with SSRI only, a currently recommended treatment for OCD. To pre-qualify for this study, patients must be between the ages of 18 and 65 years, currently taking medication for OCD, and continue to have symptoms of OCD while on medication. Additional eligibility requirements will be discussed with all potential participants prior to enrollment. Reimbursement for travel may also be provided. Please call (727) 767-8230 for more information.

Principal Investigator: Tanya Murphy, MD

Continued on page 4
For information regarding the USF Memory Disorders Clinic, please go to the following website: [www.health.usf.edu/medicine/psychiatry/memory_disorders.htm](http://www.health.usf.edu/medicine/psychiatry/memory_disorders.htm)

**RESEARCH HAPPENINGS!**

**Pediatric OCD D-Cycloserine & Cognitive Behavioral Therapy (CBT) Research Study**

The purpose of this research study is to examine if d-cycloserine enhances cognitive behavioral therapy for pediatric OCD. Participants will be involved in fifteen clinical visits spanning a nine-month period. Each participant will receive ten sessions of cognitive behavioral therapy and seven doses of the study medication or placebo one hour prior to session. Children ages 7-17 years old are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch, PhD

**Cognitive-Behavioral Therapy (CBT) for Anxiety Disorders in Children with Autism Spectrum Disorder Research Study**

The purpose of this research study is to examine the efficacy of a manualized cognitive-behavioral therapy to treat anxiety disorders in children with autism spectrum disorders. Therapy sessions last approximately one hour a week for sixteen weeks. In addition, participants will be involved in a number of anxiety and developmental assessments free of charge. Children ages 7-16 years old are eligible to participate. Please call (727) 767-8230 for more information.

Principal Investigator: Eric Storch, PhD

**Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder**

The purpose of this research study is to assess the efficacy of a form of Cognitive Behavioral Therapy (CBT), called Stepped Care CBT, that requires fewer therapy visits and utilizes family members as active components in treatment. Children and families who are interested must complete an initial assessment to determine eligibility.

Eligible participants must be between 8 and 17 years of age and have a primary diagnosis of Obsessive Compulsive Disorder. Once eligibility is determined, participants will be randomly assigned to receive Stepped Care CBT or standard CBT. Those receiving Stepped Care CBT begin treatment in “Step One” which includes 3 sessions with a therapist over the course of 6 weeks while being coached through a take-home workbook. If after 6 weeks it is determined by the research team that insufficient progress has been made, participants progress to “Step Two” which includes 9 additional therapy sessions over 9 weeks. Those receiving standard CBT will receive weekly therapy sessions for 12 weeks. Please contact Brittney Dane at (727) 767-7427 for more information.

Principal Investigator: Adam B. Lewin, PhD, ABPP

Continued on page 5
RESEARCH HAPPENINGS!

Habit Reversal Training for Children and Adolescents with Trichotillomania: A Controlled Trial

The purpose of this research study is to further investigate how well Habit Reversal Training (HRT) works to reduce hair-pulling symptoms in children and adolescents with Trichotillomania. Trichotillomania (TTM) is a condition that involves strong urges to pull out one’s own hair. Children and families who are interested must complete an initial assessment to determine eligibility. Eligible participants must be between years of age 7 and 17 and be diagnosed with TTM. All children will have the option to receive 8 weekly HRT sessions that are up to 60-minutes each. Half of all children will be chosen at random to receive these sessions immediately and the remaining half will receive the sessions after eight weeks. These sessions will focus on developing skills for managing TTM and decrease hair pulling. For more information please call (727) 767-8230 and ask for Amanda Collier.

Principal Investigators: Adam Lewin, PhD, ABPP and Omar Rahman, PhD